Description
Antimicrobial resistance is a growing concern, particularly for typhoid fever. The cefixime-ofloxacin combination offers a targeted dual-action approach—cefixime addressing extracellular pathogens and ofloxacin targeting intracellular pathogens. Clinical studies show the combination delivers rapid fever resolution (≈3 days), complete cure within ≈7 days, symptom relief, efficacy in relapse cases, and reduced hospitalization. In the face of rising resistance, cefixime-ofloxacin emerges as a safe and effective option for managing uncomplicated typhoid fever.